I know this will not happen, but I want to propose
Post# of 148109
Cytodyn is now a phase 2 trial/ peer review stage company. this is much cheaper and smaller than a phase 3 about to make money on it's drug company. there is no reason to have over a billion shares outstanding. I think phase 2 companies are at the perfect stage to get partners to go for phase 3, it should have been done that way from the start.
A nice as it might seem to use the funds to do trials, I don't want this company to take the easy road and not partner. getting a phase 3 through the FDA even with a competent CRO is obviously difficult to put it mildly. We are not here to fix the system, we need to navigate it the way it is.
$80millin can buy back 400 million shares and get us under the billion shares outstanding. this will have a huge value add to share holders and ruin shorts.
What do all of you think?